Keyword: WuXi AppTec

Taiho, Otsuka and Chugai wins KRAS-focused licensing deals. Biocon Biologics nabs PE funding before planned IPO. Mark Alles joins Antengene's board.

CDMO WuXi STA has expanded its Changzhou, China site with a facility to manufacture oligonucleotide APIs including DNAs and RNAs.

Teva will produce its new migraine drug at a plant in Israel and more news of note.

Avanir pays $116 million in Neudexta kickback suits; China unveils results for a procurement scheme; Aurobindo founder faces insider trading fine.

Biocon's manufacturing problems cost it and Mylan again; CStone's CEO racks up nearly $20 million in 2018 pay; Novartis sells Suzhou plant.

Here is some news of note for the week. 

Takeda sells meds to Novartis and J&J; Daiichi's AZ-shared HER2 antibody-drug conjugate hits key trial goal; Sun scouts for Chinese partner.

Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.

GSK sells Indian vaccine subsidiary to Bharat; Dr. Reddy's rides a turbulent week; Sandoz sells more U.S. generics.

Pfizer closes two Hospira plants in India; Gilead licenses Yuhan's NASH programs; Fujifilm is expanding its footprint in the U.S.